Loading...

TARA PROTARA THERAPEUTICS INC Disposals and divestitures 8-K Filing

PRTR

TR

PROTARA THERAPEUTICS INC

(TARA)

2025 8-K

Stock Offering Details

Investor Update

Investor Presentation Released

Financial Results Report

Financial Statements

Financial Results

Clinical Trial Update

Financial Results

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

Private Placement

Resignation of Chief Medica...

Financial Results Announcement

Financial Results Announcement

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

FDA Clearance for Phase 2 T...

Positive Preliminary Data A...

Disclosure of Cash Holdings...

Financial Results Announcement

Appointment of CFO

Corporate Presentation

External Links:

Protara Therapeutics, Inc. reported positive interim clinical results for its ongoing Phase 2 ADVANCED-2 trial on April 26, 2025, featuring a 100% complete response rate in BCG-Unresponsive patients and a 76% rate in BCG-Naïve patients. The company also held an investor presentation on April 28, 2025, to discuss these findings, which included the data from clinical trials.

AI Assistant

PROTARA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.